Spatial transcriptomics revolutionizes cancer research. Researchers map gene expression while preserving tissue location. This method reveals the tumor microenvironment (TME) in detail.
Scientists use spatial transcriptomics to study cell interactions. Tumor cells communicate with immune cells, fibroblasts, and endothelial cells. Moreover, the technique uncovers spatial patterns. These patterns drive tumor growth, invasion, and therapy resistance.
Furthermore, advanced platforms provide high resolution. Tools like Visium, CosMx, MERFISH, and Xenium capture transcripts in situ. Therefore, researchers identify distinct zones within tumors. For example, tumor core differs from the leading edge. Core regions often show proliferative signals. Edge areas display invasive and mesenchymal traits.
Additionally, spatial data highlights immune suppression. Macrophages and other cells create immunosuppressive niches. These niches help tumors evade immune attacks. Studies show conserved architectures across cancers. Such patterns predict patient survival and treatment response.
Moreover, integration with single-cell RNA sequencing boosts insights. Researchers deconvolute cell types in spots. They analyze ligand-receptor interactions. This reveals communication pathways that sustain the TME.
Recent advances improve detection in FFPE samples. These samples come from archived tissues. Platforms now achieve single-cell or near-single-cell resolution. Consequently, inter- and intra-tumor heterogeneity becomes clearer.
Spatial transcriptomics guides precision oncology. It identifies biomarkers in spatial context. Clinicians use it to understand therapy resistance. For instance, certain spatial subtypes link to better or worse outcomes.
Overall, this technology transforms our view of cancer biology. Researchers uncover how microenvironment organization influences disease progression. Thus, it paves the way for targeted therapies and improved diagnostics.
CMP Bio World 